Ovarian Cancer Therapeutics market worldwide is projected to grow by US$4. 7 Billion, driven by a compounded growth of 22. 1%. PARP Inhibitors, one of the segments analyzed and sized in this study, displays the potential to grow at over 23.

New York, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Ovarian Cancer Therapeutics Industry" - https://www.reportlinker.com/p05817618/?utm_source=GNW
4%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$3.7 Billion by the year 2025, PARP Inhibitors will bring in healthy gains adding significant momentum to global growth.

- Representing the developed world, the United States will maintain a 20.4% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$201.6 Million to the region’s size and clout in the next 5 to 6 years. Over US$171.5 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, PARP Inhibitors will reach a market size of US$189.1 Million by the close of the analysis period. As the world’s second largest economy and the new game changer in global markets, China exhibits the potential to grow at 26.3% over the next couple of years and add approximately US$1.1 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

- Competitors identified in this market include among others, AstraZeneca PLC; Clovis Oncology; Genentech, Inc.; Tesaro, Inc.


Read the full report: https://www.reportlinker.com/p05817618/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Global Competitor Market Shares
Ovarian Cancer Therapeutics Competitor Market Share Scenario
Worldwide (in %): 2019 & 2028
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: Ovarian Cancer Therapeutics Global Market Estimates
and Forecasts in US$ Thousand by Region/Country: 2018-2025
Table 2: Ovarian Cancer Therapeutics Global Retrospective
Market Scenario in US$ Thousand by Region/Country: 2009-2017
Table 3: Ovarian Cancer Therapeutics Market Share Shift across
Key Geographies Worldwide: 2009 VS 2019 VS 2025
Table 4: PARP Inhibitors (Therapeutic Class) World Market by
Region/Country in US$ Thousand: 2018 to 2025
Table 5: PARP Inhibitors (Therapeutic Class) Historic Market
Analysis by Region/Country in US$ Thousand: 2009 to 2017
Table 6: PARP Inhibitors (Therapeutic Class) Market Share
Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS
2025
Table 7: Angiogenesis Inhibitors (Therapeutic Class) Potential
Growth Markets Worldwide in US$ Thousand: 2018 to 2025
Table 8: Angiogenesis Inhibitors (Therapeutic Class) Historic
Market Perspective by Region/Country in US$ Thousand: 2009 to
2017
Table 9: Angiogenesis Inhibitors (Therapeutic Class) Market
Sales Breakdown by Region/Country in Percentage: 2009 VS 2019
VS 2025
Table 10: PD-L1 Inhibitors (Therapeutic Class) Geographic
Market Spread Worldwide in US$ Thousand: 2018 to 2025
Table 11: PD-L1 Inhibitors (Therapeutic Class) Region Wise
Breakdown of Global Historic Demand in US$ Thousand: 2009 to
2017
Table 12: PD-L1 Inhibitors (Therapeutic Class) Market Share
Distribution in Percentage by Region/Country: 2009 VS 2019 VS
2025

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS
UNITED STATES
Market Facts & Figures
US Ovarian Cancer Therapeutics Market Share (in %) by Company:
2019 & 2025
Table 13: United States Ovarian Cancer Therapeutics Market
Estimates and Projections in US$ Thousand by Therapeutic Class:
2018 to 2025
Table 14: Ovarian Cancer Therapeutics Market in the United
States by Therapeutic Class: A Historic Review in US$ Thousand
for 2009-2017
Table 15: United States Ovarian Cancer Therapeutics Market
Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
CANADA
Table 16: Canadian Ovarian Cancer Therapeutics Market Estimates
and Forecasts in US$ Thousand by Therapeutic Class: 2018 to
2025
Table 17: Canadian Ovarian Cancer Therapeutics Historic Market
Review by Therapeutic Class in US$ Thousand: 2009-2017
Table 18: Ovarian Cancer Therapeutics Market in Canada:
Percentage Share Breakdown of Sales by Therapeutic Class for
2009, 2019, and 2025
JAPAN
Table 19: Japanese Market for Ovarian Cancer Therapeutics:
Annual Sales Estimates and Projections in US$ Thousand by
Therapeutic Class for the Period 2018-2025
Table 20: Ovarian Cancer Therapeutics Market in Japan: Historic
Sales Analysis in US$ Thousand by Therapeutic Class for the
Period 2009-2017
Table 21: Japanese Ovarian Cancer Therapeutics Market Share
Analysis by Therapeutic Class: 2009 VS 2019 VS 2025
CHINA
Table 22: Chinese Ovarian Cancer Therapeutics Market Growth
Prospects in US$ Thousand by Therapeutic Class for the Period
2018-2025
Table 23: Ovarian Cancer Therapeutics Historic Market Analysis
in China in US$ Thousand by Therapeutic Class: 2009-2017
Table 24: Chinese Ovarian Cancer Therapeutics Market by
Therapeutic Class: Percentage Breakdown of Sales for 2009,
2019, and 2025
EUROPE
Market Facts & Figures
European Ovarian Cancer Therapeutics Market: Competitor Market
Share Scenario (in %) for 2019 & 2025
Table 25: European Ovarian Cancer Therapeutics Market Demand
Scenario in US$ Thousand by Region/Country: 2018-2025
Table 26: Ovarian Cancer Therapeutics Market in Europe: A
Historic Market Perspective in US$ Thousand by Region/Country
for the Period 2009-2017
Table 27: European Ovarian Cancer Therapeutics Market Share
Shift by Region/Country: 2009 VS 2019 VS 2025
Table 28: European Ovarian Cancer Therapeutics Market Estimates
and Forecasts in US$ Thousand by Therapeutic Class: 2018-2025
Table 29: Ovarian Cancer Therapeutics Market in Europe in US$
Thousand by Therapeutic Class: A Historic Review for the Period
2009-2017
Table 30: European Ovarian Cancer Therapeutics Market Share
Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
FRANCE
Table 31: Ovarian Cancer Therapeutics Market in France by
Therapeutic Class: Estimates and Projections in US$ Thousand
for the Period 2018-2025
Table 32: French Ovarian Cancer Therapeutics Historic Market
Scenario in US$ Thousand by Therapeutic Class: 2009-2017
Table 33: French Ovarian Cancer Therapeutics Market Share
Analysis by Therapeutic Class: 2009 VS 2019 VS 2025
GERMANY
Table 34: Ovarian Cancer Therapeutics Market in Germany: Recent
Past, Current and Future Analysis in US$ Thousand by
Therapeutic Class for the Period 2018-2025
Table 35: German Ovarian Cancer Therapeutics Historic Market
Analysis in US$ Thousand by Therapeutic Class: 2009-2017
Table 36: German Ovarian Cancer Therapeutics Market Share
Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
ITALY
Table 37: Italian Ovarian Cancer Therapeutics Market Growth
Prospects in US$ Thousand by Therapeutic Class for the Period
2018-2025
Table 38: Ovarian Cancer Therapeutics Historic Market Analysis
in Italy in US$ Thousand by Therapeutic Class: 2009-2017
Table 39: Italian Ovarian Cancer Therapeutics Market by
Therapeutic Class: Percentage Breakdown of Sales for 2009,
2019, and 2025
UNITED KINGDOM
Table 40: United Kingdom Market for Ovarian Cancer
Therapeutics: Annual Sales Estimates and Projections in US$
Thousand by Therapeutic Class for the Period 2018-2025
Table 41: Ovarian Cancer Therapeutics Market in the United
Kingdom: Historic Sales Analysis in US$ Thousand by Therapeutic
Class for the Period 2009-2017
Table 42: United Kingdom Ovarian Cancer Therapeutics Market
Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025
SPAIN
Table 43: Spanish Ovarian Cancer Therapeutics Market Estimates
and Forecasts in US$ Thousand by Therapeutic Class: 2018 to
2025
Table 44: Spanish Ovarian Cancer Therapeutics Historic Market
Review by Therapeutic Class in US$ Thousand: 2009-2017
Table 45: Ovarian Cancer Therapeutics Market in Spain:
Percentage Share Breakdown of Sales by Therapeutic Class for
2009, 2019, and 2025
RUSSIA
Table 46: Russian Ovarian Cancer Therapeutics Market Estimates
and Projections in US$ Thousand by Therapeutic Class: 2018 to
2025
Table 47: Ovarian Cancer Therapeutics Market in Russia by
Therapeutic Class: A Historic Review in US$ Thousand for
2009-2017
Table 48: Russian Ovarian Cancer Therapeutics Market Share
Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
REST OF EUROPE
Table 49: Rest of Europe Ovarian Cancer Therapeutics Market
Estimates and Forecasts in US$ Thousand by Therapeutic Class:
2018-2025
Table 50: Ovarian Cancer Therapeutics Market in Rest of Europe
in US$ Thousand by Therapeutic Class: A Historic Review for the
Period 2009-2017
Table 51: Rest of Europe Ovarian Cancer Therapeutics Market
Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
ASIA-PACIFIC
Table 52: Asia-Pacific Ovarian Cancer Therapeutics Market
Estimates and Forecasts in US$ Thousand by Region/Country:
2018-2025
Table 53: Ovarian Cancer Therapeutics Market in Asia-Pacific:
Historic Market Analysis in US$ Thousand by Region/Country for
the Period 2009-2017
Table 54: Asia-Pacific Ovarian Cancer Therapeutics Market Share
Analysis by Region/Country: 2009 VS 2019 VS 2025
Table 55: Ovarian Cancer Therapeutics Market in Asia-Pacific by
Therapeutic Class: Estimates and Projections in US$ Thousand
for the Period 2018-2025
Table 56: Asia-Pacific Ovarian Cancer Therapeutics Historic
Market Scenario in US$ Thousand by Therapeutic Class: 2009-2017
Table 57: Asia-Pacific Ovarian Cancer Therapeutics Market Share
Analysis by Therapeutic Class: 2009 VS 2019 VS 2025
AUSTRALIA
Table 58: Ovarian Cancer Therapeutics Market in Australia:
Recent Past, Current and Future Analysis in US$ Thousand by
Therapeutic Class for the Period 2018-2025
Table 59: Australian Ovarian Cancer Therapeutics Historic
Market Analysis in US$ Thousand by Therapeutic Class: 2009-2017
Table 60: Australian Ovarian Cancer Therapeutics Market Share
Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
INDIA
Table 61: Indian Ovarian Cancer Therapeutics Market Estimates
and Forecasts in US$ Thousand by Therapeutic Class: 2018 to
2025
Table 62: Indian Ovarian Cancer Therapeutics Historic Market
Review by Therapeutic Class in US$ Thousand: 2009-2017
Table 63: Ovarian Cancer Therapeutics Market in India:
Percentage Share Breakdown of Sales by Therapeutic Class for
2009, 2019, and 2025
SOUTH KOREA
Table 64: Ovarian Cancer Therapeutics Market in South Korea:
Recent Past, Current and Future Analysis in US$ Thousand by
Therapeutic Class for the Period 2018-2025
Table 65: South Korean Ovarian Cancer Therapeutics Historic
Market Analysis in US$ Thousand by Therapeutic Class: 2009-2017
Table 66: Ovarian Cancer Therapeutics Market Share Distribution
in South Korea by Therapeutic Class: 2009 VS 2019 VS 2025
REST OF ASIA-PACIFIC
Table 67: Rest of Asia-Pacific Market for Ovarian Cancer
Therapeutics: Annual Sales Estimates and Projections in US$
Thousand by Therapeutic Class for the Period 2018-2025
Table 68: Ovarian Cancer Therapeutics Market in Rest of
Asia-Pacific: Historic Sales Analysis in US$ Thousand by
Therapeutic Class for the Period 2009-2017
Table 69: Rest of Asia-Pacific Ovarian Cancer Therapeutics
Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS
2025
LATIN AMERICA
Table 70: Latin American Ovarian Cancer Therapeutics Market
Trends by Region/Country in US$ Thousand: 2018-2025
Table 71: Ovarian Cancer Therapeutics Market in Latin America
in US$ Thousand by Region/Country: A Historic Perspective for
the Period 2009-2017
Table 72: Latin American Ovarian Cancer Therapeutics Market
Percentage Breakdown of Sales by Region/Country: 2009, 2019,
and 2025
Table 73: Latin American Ovarian Cancer Therapeutics Market
Growth Prospects in US$ Thousand by Therapeutic Class for the
Period 2018-2025
Table 74: Ovarian Cancer Therapeutics Historic Market Analysis
in Latin America in US$ Thousand by Therapeutic Class:
2009-2017
Table 75: Latin American Ovarian Cancer Therapeutics Market by
Therapeutic Class: Percentage Breakdown of Sales for 2009,
2019, and 2025
ARGENTINA
Table 76: Argentinean Ovarian Cancer Therapeutics Market
Estimates and Forecasts in US$ Thousand by Therapeutic Class:
2018-2025
Table 77: Ovarian Cancer Therapeutics Market in Argentina in
US$ Thousand by Therapeutic Class: A Historic Review for the
Period 2009-2017
Table 78: Argentinean Ovarian Cancer Therapeutics Market Share
Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
BRAZIL
Table 79: Ovarian Cancer Therapeutics Market in Brazil by
Therapeutic Class: Estimates and Projections in US$ Thousand
for the Period 2018-2025
Table 80: Brazilian Ovarian Cancer Therapeutics Historic Market
Scenario in US$ Thousand by Therapeutic Class: 2009-2017
Table 81: Brazilian Ovarian Cancer Therapeutics Market Share
Analysis by Therapeutic Class: 2009 VS 2019 VS 2025
MEXICO
Table 82: Ovarian Cancer Therapeutics Market in Mexico: Recent
Past, Current and Future Analysis in US$ Thousand by
Therapeutic Class for the Period 2018-2025
Table 83: Mexican Ovarian Cancer Therapeutics Historic Market
Analysis in US$ Thousand by Therapeutic Class: 2009-2017
Table 84: Mexican Ovarian Cancer Therapeutics Market Share
Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
REST OF LATIN AMERICA
Table 85: Rest of Latin America Ovarian Cancer Therapeutics
Market Estimates and Projections in US$ Thousand by Therapeutic
Class: 2018 to 2025
Table 86: Ovarian Cancer Therapeutics Market in Rest of Latin
America by Therapeutic Class: A Historic Review in US$ Thousand
for 2009-2017
Table 87: Rest of Latin America Ovarian Cancer Therapeutics
Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS
2025
MIDDLE EAST
Table 88: The Middle East Ovarian Cancer Therapeutics Market
Estimates and Forecasts in US$ Thousand by Region/Country:
2018-2025
Table 89: Ovarian Cancer Therapeutics Market in the Middle East
by Region/Country in US$ Thousand: 2009-2017
Table 90: The Middle East Ovarian Cancer Therapeutics Market
Share Breakdown by Region/Country: 2009, 2019, and 2025
Table 91: The Middle East Ovarian Cancer Therapeutics Market
Estimates and Forecasts in US$ Thousand by Therapeutic Class:
2018 to 2025
Table 92: The Middle East Ovarian Cancer Therapeutics Historic
Market by Therapeutic Class in US$ Thousand: 2009-2017
Table 93: Ovarian Cancer Therapeutics Market in the Middle
East: Percentage Share Breakdown of Sales by Therapeutic Class
for 2009, 2019, and 2025
IRAN
Table 94: Iranian Market for Ovarian Cancer Therapeutics:
Annual Sales Estimates and Projections in US$ Thousand by
Therapeutic Class for the Period 2018-2025
Table 95: Ovarian Cancer Therapeutics Market in Iran: Historic
Sales Analysis in US$ Thousand by Therapeutic Class for the
Period 2009-2017
Table 96: Iranian Ovarian Cancer Therapeutics Market Share
Analysis by Therapeutic Class: 2009 VS 2019 VS 2025
ISRAEL
Table 97: Israeli Ovarian Cancer Therapeutics Market Estimates
and Forecasts in US$ Thousand by Therapeutic Class: 2018-2025
Table 98: Ovarian Cancer Therapeutics Market in Israel in US$
Thousand by Therapeutic Class: A Historic Review for the Period
2009-2017
Table 99: Israeli Ovarian Cancer Therapeutics Market Share
Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
SAUDI ARABIA
Table 100: Saudi Arabian Ovarian Cancer Therapeutics Market
Growth Prospects in US$ Thousand by Therapeutic Class for the
Period 2018-2025
Table 101: Ovarian Cancer Therapeutics Historic Market Analysis
in Saudi Arabia in US$ Thousand by Therapeutic Class: 2009-2017
Table 102: Saudi Arabian Ovarian Cancer Therapeutics Market by
Therapeutic Class: Percentage Breakdown of Sales for 2009,
2019, and 2025
UNITED ARAB EMIRATES
Table 103: Ovarian Cancer Therapeutics Market in the United
Arab Emirates: Recent Past, Current and Future Analysis in US$
Thousand by Therapeutic Class for the Period 2018-2025
Table 104: United Arab Emirates Ovarian Cancer Therapeutics
Historic Market Analysis in US$ Thousand by Therapeutic Class:
2009-2017
Table 105: Ovarian Cancer Therapeutics Market Share
Distribution in United Arab Emirates by Therapeutic Class: 2009
VS 2019 VS 2025
REST OF MIDDLE EAST
Table 106: Ovarian Cancer Therapeutics Market in Rest of Middle
East: Recent Past, Current and Future Analysis in US$ Thousand
by Therapeutic Class for the Period 2018-2025
Table 107: Rest of Middle East Ovarian Cancer Therapeutics
Historic Market Analysis in US$ Thousand by Therapeutic Class:
2009-2017
Table 108: Rest of Middle East Ovarian Cancer Therapeutics
Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS
2025
AFRICA
Table 109: African Ovarian Cancer Therapeutics Market Estimates
and Projections in US$ Thousand by Therapeutic Class: 2018 to
2025
Table 110: Ovarian Cancer Therapeutics Market in Africa by
Therapeutic Class: A Historic Review in US$ Thousand for
2009-2017
Table 111: African Ovarian Cancer Therapeutics Market Share
Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025

IV. COMPETITION

TESARO, INC.
GENENTECH, INC.
ASTRAZENECA PLC
CLOVIS ONCOLOGY
AMGEN
BRISTOL-MYERS SQUIBB COMPANY
CHUGAI PHARMACEUTICAL
DR. REDDY’S LABORATORIES LTD.
ELI LILLY AND COMPANY
GLAXOSMITHKLINE PLC
MEDIMMUNE
ROCHE DIAGNOSTICS CORPORATION

V. CURATED RESEARCH
Read the full report: https://www.reportlinker.com/p05817618/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.